Callan Family Office LLC Makes New Investment in Haleon plc (NYSE:HLN)

Callan Family Office LLC purchased a new position in Haleon plc (NYSE:HLN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 206,499 shares of the company’s stock, valued at approximately $1,970,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. FMR LLC grew its position in Haleon by 5.8% in the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after buying an additional 5,768,117 shares during the last quarter. Wellington Management Group LLP grew its position in Haleon by 49.9% in the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after buying an additional 3,046,841 shares during the last quarter. Douglas Lane & Associates LLC grew its position in Haleon by 1.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock worth $82,274,000 after buying an additional 161,865 shares during the last quarter. JPMorgan Chase & Co. grew its position in Haleon by 25.3% in the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after buying an additional 1,026,939 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Haleon during the 4th quarter worth approximately $42,193,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Up 0.5 %

NYSE HLN opened at $10.45 on Friday. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $47.29 billion, a PE ratio of 30.72, a price-to-earnings-growth ratio of 2.82 and a beta of 0.25. The firm’s fifty day simple moving average is $9.66 and its 200-day simple moving average is $9.86.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. As a group, sell-side analysts anticipate that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The business also recently declared a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a $0.1166 dividend. The ex-dividend date of this dividend is Friday, April 25th. This is an increase from Haleon’s previous — dividend of $0.05. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio is 58.97%.

Analysts Set New Price Targets

Several analysts have issued reports on HLN shares. Hsbc Global Res downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Morgan Stanley downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. HSBC reissued a “hold” rating on shares of Haleon in a research note on Wednesday. Finally, Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Five equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.